HYBRID RISK ADJUSTMENT FOR PHARMACEUTICAL BENEFITS

MANUEL GARCÍA-GOÑI
PERE IBERN
JOSÉ MARÍA INORIZA

FUNDACIÓN DE LAS CAJAS DE AHORROS
DOCUMENTO DE TRABAJO
Nº 399/2008

De conformidad con la base quinta de la convocatoria del Programa de Estímulo a la Investigación, este trabajo ha sido sometido a evaluación externa anónima de especialistas cualificados a fin de contrastar su nivel técnico.

ISSN: 1988-8767

La serie **DOCUMENTOS DE TRABAJO** incluye avances y resultados de investigaciones dentro de los programas de la Fundación de las Cajas de Ahorros.
Las opiniones son responsabilidad de los autores.

Title: Hybrid Risk Adjustment for Pharmaceutical Benefits

Authors and addresses:

Communicating author:

Manuel García-Goñi
Departamento de Economía Aplicada II
Universidad Complutense de Madrid
Campus de Somosaguas
28223 Pozuelo de Alarcón, Madrid
SPAIN
Email: mggoni@ccee.ucm.es
Tel +34913943235
Fax +34913942457

Other authors:

Pere Ibern
Centre de Recerca en Economia i Salut
Departament d'Economia i Empresa
Universitat Pompeu Fabra
Ramon Trias Fargas, 25-27
08005 Barcelona.
SPAIN

José María Inoriza
Serveis de Salut Integrats Baix Empordà
Departament Avaluacio Informacio i Recerca
Hospital de Palamós
Hospital, 36
17230 Palamós, Girona
SPAIN

Hybrid Risk Adjustment for Pharmaceutical Benefits

Abstract

This paper analyses the application of hybrid risk adjustment versus either only prospective or only concurrent risk adjustment formulae in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organization in Catalonia during years 2002 and 2003. We apply a mixed formula and find that a hybrid risk adjustment model maximizes incentives for efficiency in the provision of low risk individuals by reducing within-group variation of drug expenditures and at the same time eliminates incentives for risk selection for a specific set of high risk individuals through the use of concurrent reimbursement.

Keywords: drug expenditure, hybrid risk-adjustment, morbidity, clinical risk groups.

JEL Classification: I18

1. Introduction

Two major trends regarding pharmaceutical expenditure are currently taking place in developed countries. On one hand, generic drugs introduction contribute to a decrease in unit prices. On the other, new expensive and innovative molecules are being approved by drug regulatory agencies. The final impact of this trend is still unknown, although some initial effects are being observed. For example, concentration of pharmaceutical expenditures among most costly consumers is very high. While US top 10% consumers represented 66% of pharmaceutical expenditures in 1996, in 2003 this proportion decreased slightly to 64%, however, spending per person has more than doubled from $1,823 to $3,925 [32].

Such concentration in drug expenditure and in general in health expenditure has strong implications on access and funding of new drugs [17], raises equity concerns [18] and may promote incentives for risk selection [4]. However, beyond these facts there are relevant changes in population morbidity and mortality and some of them are clearly related with health care resources, drugs and medical innovation.

Understanding population patterns of drug consumption, costs and morbidity are less usual since individual data are divided between different sources in fragmented health care systems. There exists, however, recent research showing the link between prescription drug expenditures and population demographic [16].

When citizens are covered under universal coverage and public funding, there is a need for tools to allocate resources for drug expenditures at a population level, which attempt to get value for money. In such situation, understanding morbidity becomes a key issue.

Several initiatives have been developed for setting prescription drugs budgets in primary care, including the addition of incentives [20] and the understanding of its variation [11,12]. However, the prescription drug budget affects all levels of care and not only primary care. The right approach should therefore allow for resource allocation at a population level including all types of drug expenditures.

Under the term risk-adjustment there are several approaches aimed at explaining and predicting costs and utilization of the population using health status data. These models are potentially useful in order to compensate insurers and providers according to the risk they assume as reviewed in the literature [26,10]. In health care payment systems design, any resource allocation has to solve the crucial trade-off between efficiency and selection [19,24]. Risk adjustment has also been used to examine the economic profiling of physicians when claims data are grouped into episodes of care [23]. Although most of risk adjustment studies refer to the US population, there are others referring to European countries as for example Germany [3] or Spain [10] and for other countries as Australia [1]. Too much emphasis on efficiency may promote incentives for selection of patients, benefits (or both). Therefore we have to split the role of risk-adjustment as a mechanism that contributes to understand cost and utilization according to health status, from payment systems that may use the risk-adjustment methodologies as an element in the incentive design. Results in terms of incentives for efficiency and risk selection are sensitive to the type of information used in the payment system and depend on the specific environment. For example, risk selection practices are expected to be less relevant when universal coverage is effective. Thus, while including in the risk adjustment formula only ex ante (prospective) individual information promote incentives for efficiency because health plans can benefit of the savings in the cut of drug expenditures, they also may benefit from selecting patients or benefits. Differently, including ex post (concurrent) information on costs in the payment formula, in what has been called in the literature a risk sharing formula [25,27], reduces the risk assumed by health plans, and therefore the incentives for risk selection, although also the incentives for efficiency. The use of a mixed payment system for total health expenditures started to be explored in the literature in the last decades [2,7,14]. However, there is a relatively new literature addressing specifically the predictability of drug expenditures [29,30,31] and the use of a mixed or hybrid risk adjustment formula with both prospective and concurrent information with the aim of maximizing incentives for efficiency while minimizing incentives for risk selection [6,15]. In a former article [10], we have shown the extent of predictability of pharmaceutical expenditure (and compared our results to other articles in the literature) according to morbidity grouped with the use of the Clinical Risk Groups classification

system under different specification models applying risk adjustment. A recent comparison of the different information systems has been provided by the Society of Actuaries [28]

In this article, we use individual data and analyze the relationship between drug expenditures and morbidity for the population belonging to an integrated healthcare organization covered by the public health system in Catalonia, in the context of the Spanish National Health System. It is important to note that with a universal coverage all patients access health care. However, there potentially exist incentives for a subtle risk selection in which high cost patients might be deviated to different departments within the integrated care organization or to different primary care health areas. Thus, integrated healthcare systems are increasingly searching for tools to allocate budgets and set the right incentives for pharmaceutical expenditure. We consider risk adjustment as a tool able to identify the efficient and inefficient departments of a healthcare organization. Besides, the use of a hybrid formula in the allocation of budgets including concurrent information for patients with specific conditions which tend to concentrate drug expenditures benefits from its higher predictive power and reduces incentives for risk selection by compensating deviations in drug expenditures which are explained by morbidity.

2. Data Sources

We use individual data on prescription drug consumption and morbidity from an integrated healthcare organization, Serveis Sanitaris Integrats del Baix Empordà (SSIBE), in Catalonia. The organization provides publicly funded health services (hospital care, primary care, and long-term care) to the population in the county of Baix Empordà. The providers taken into account are: Palamós Hospital, which has 100 beds for acute patients and 50 for skilled nursing care, and 4 Primary Care Centers. Although citizens may also receive benefits outside the organization, the data on benefits and costs from outside the organization were not available. SSIBE has an information system that integrates clinical activities and costs. The main features that define this information system are: (1) unique identification patient files for all encounters (primary care, specialized care, and inpatient services) and (2) decentralized activity file codified

in ICD-9-CM by clinicians and reviewed by documentalists. The identification of each encounter allows the costs allocation, as in our case, pharmacy costs.

This research uses the following anonymized databases belonging to years 2002 and 2003: population database, encounters database, and pharmacy database. The first population database was created with the information relative to all the resident population in Baix Empordà: 116,936 citizens. This paper is based only on the analysis of 4 Health Basic Areas (ABS) managed by SSIBE and it refers to morbidity and pharmaceutical expenditure of 87,436 members who were covered during years 2002 and 2003 by the integrated delivery system. Morbidity measurement is performed by the aggregation of the information on codified encounters of the population with the organization (1,290,642 diagnosis and procedures codes). Among the possible risk adjustment systems, in this article we use the *Clinical Risk Groups* (CRGs) (version 1.2B) which allows classifying individuals in mutually exclusive categories while preserving clinical significance, and taking into account co-morbidities and severity levels [13]. From the three different models provided by the CRG software, we use the concurrent model. For each patient we get a unique CRG as well as its corresponding aggregation in ACRG1, ACRG2 and ACRG3. In this paper we describe the population through the highest level of aggregation (ACRG3) and for the estimations we use the second level of aggregation ACRG2 for the classification of patients in morbidity groups. This level of aggregation originally has 176 mutually exclusive categories. However we slightly modify those into 82 mutually exclusive categories fully maintaining its clinical significance by joining patients belonging to different CRGs of the same category but with different levels of severity, in order to avoid over fitting in our estimation because of a very low number of patients in some groups.

Pharmaceutical expenditure information refers both to prescriptions provided by pharmacists publicly financed by Servei Català de Salut (CatSalut) and to prescriptions to inpatients and medical ambulatory supply to ambulatory patients. Therefore, we include in the analysis ambulatory pharmaceutical prescriptions by the doctors belonging to SSIBE and billed by pharmacists, but also primary care, and specialized care prescriptions; and the total pharmaceutical expenditure includes both public financing and private copayment (with a total of 1,206,008 primary care prescriptions that sum up 14,028,102€ in year 2002). This

consumption information incorporates residents as well as other persons that received services from SSIBE. Also it includes resident people with charge to international agreements or people whom they have provisional authentication codes. This means that the total pharmaceutical consumption in the region cannot be fully allocated because part of this consumption does not correspond with the resident's file. Finally, pharmaceuticals consumers in 2002 were 50,280 (57.5 % of the population) with a total individually allocated expenditures of 13,026,913€, from which there is a primary care prescriptions expenditure of 12,091,603€ and a hospital expenditure of 935,310€. Pharmaceutical consumption corresponding to prescriptions beyond SSIBE physicians or OTC drugs was not available.

Table 1 provides the descriptive statistics of the sample. The population is almost equally distributed between males (50.53%) and females (49.47%), and the average pharmaceutical cost has increased from 148.94 euros in 2002 to 182.68 euros in 2003, with 42.50% in 2002 and 38.64% of the population having zero drug expenditure. From table 2, we also observe how most of the patients belong to the healthy condition under the most aggregated classification system (65342 patients representing 74.73% of the sample in 2002 and 63958 patients representing 73.15% of the sample in 2003) while only a few belong to the highest severity group which classifies to the catastrophic condition (125 patients representing 0.14% of the sample in 2002 and 135 patients representing 0.15% of the sample in 2003). From the subgroup of patients with zero drug expenditures, most of them, 95% are classified as healthy (35,421 out of 37,162 in 2002 and 32,397 out of 33,788 in 2003).

3. Study design

This paper estimates prospective, concurrent, and hybrid models using different information sets in order to predict drug expenditures in the subsequent year. Our objective is to examine the predictive power of each model, how well they explain future cost, and provide implications in terms of the application of a hybrid payment formula in the incentives of efficiency and risk selection in the pharmaceutical market. The basic model is provided by:

$$DrugExp_{i,t} = f(demo_{i,t-1}, HS_{i,t-1,t}, \varepsilon_{i,t})$$

Thus, the dependent variable, drug expenditures in year *t* for individual *i*, is explained by some independent variables or risk adjusters (individual demographic characteristics and health status information). Demographic information is provided by twelve age-gender cells. Prospective risk adjustment models predict actual drug expenditure with information on demographic characteristics and clinical status condition in year *t-1*. Differently, concurrent risk adjustment models predict actual drug expenditure using demographic and actual information on clinical status. Hybrid risk adjustment models combine both prospective and concurrent models. Pure prospective models promote incentives for efficiency but they are unable to avoid risk selection. Differently, the use of concurrent reimbursement models, as those based on actual information on cost (risk sharing) or health status (concurrent risk adjustment), presents lower incentives for risk selection because payment is associated to actual information, but incentives for efficiency are also reduced.. The only use of diagnosis-based risk adjustment models does not solve the problem of risk selection because they do not capture within-condition variation even with concurrent information [8]. Therefore, we propose the use of a hybrid risk adjustment model with information on health conditions different to the classification system used in the risk adjustment model, trying to rescue the positive properties of both prospective and concurrent formulae. The hybrid model will promote incentives for efficiency as in the prospective model for most of the population, but will reduce incentives for risk selection for those patients suffering specific health conditions. The reimbursement associated to the second type of patients under the hybrid systems is set as a concurrent payment. In order to divide the population into two parts (one for the prospective payment and the other for the concurrent payment), we utilize the set of 100 verifiable, expensive, predictive conditions (VEP100) already used and presented in the literature [6]. The appropriateness of those conditions stems from the fact that being verifiable (based on objective clinical measures) it is avoided the risk of classifying to this set of patients simply to any expensive patient; being expensive and predictive we select the type of patients that might be at risk of suffering risk selection because of for example, long term treatments.

Because the set of VEP100 conditions in our Spanish sample might be different from that of the U.S. in the literature, we checked its validity by comparing the relative cost weights of the set of

patients with and without VEP100 conditions presented in table 1. As expected, patients suffering at least one of the specific VEP100 conditions systematically present drug expenditures much higher than the rest of patients (603€ versus 92€ in 2002 and 724€ versus 106€ in 2003). Because the problem of risk adjustment models is due to the within-group variation in expected expenditures, we check the distribution of the appearance of VEP100 conditions under the CRG classification system. In table 2 we observe how in relative terms, 96% of healthy patients do not suffer any VEP100 conditions, while increasing the level of severity in the CRGs supposes increase also the proportion of patients with at least one VEP100 condition until around 97% of patients in the catastrophic conditions group. However, it is important to note that in absolute terms about 23% of all patients suffering at least one VEP100 condition (2,165 out of 9,629 in 2002 and 2,473 out of 10,730 in 2003) belong to the healthy group promoting incentives for risk selection. Therefore, we utilize the same VEP100 conditions classification which allows also comparison with other works in the literature.
In this article, the specification used in the estimations is the linear regression since although other specifications are considered in an earlier work [10], they do not significantly increase the predictive power while linear regression keeps simplicity in the interpretation for health policy makers. Other alternatives are also being explored in the risk adjustment literature, as the use of regression tree boosting to risk adjust health care cost predictions [21].

4. Main findings

Table 3 presents the R^2 of the different risk adjustment models for predicting drug expenditures. Model 1 only includes demographic information and obtains an R^2 of about 0.09. However, including health status information in the prospective model (models 2), the predictive power increases until an R^2 of 0.21 (only CRG information in model 2a), 0.24 (demographic and CRG information in model 2b) and 0.27 (demographic, CRG information, and presence of at least one VEP100 condition in model 2c). Thus, the higher is the quality of the information used in the prospective model, the better is the predictive power, and including a dummy variable with the presence of a VEP100 condition improves the usual prospective model of the usual risk adjustment model that uses the CRG classification system. Concurrent models 3a to 3c (using

only CRG information, demographic and CRGs, or demographic, CRGs and presence of VEP100 conditions respectively) behaves equally and increases the proportion of explained variance to a highest value of R^2=0.2893 (model 3c). When dividing population into two parts depending on the presence of at least one VEP100 condition, the R^2 in the prospective models for patients without those conditions increases and is similar to that of the concurrent model for the whole population, with an R^2 of 0.2769 (model 5c). The reason is that we have eliminated from that sample patients suffering VEP100 conditions (12.27% of the sample), who present a high variation of drug expenditures within CRG categories. At the same time, even in concurrent models, the R^2 of models for those patients with high variation in drug expenditures decreases to 0.2099 (model 4c). The hybrid models take into account the two sub-samples with concurrent information for patients with at least one VEP100 condition and prospective information for patients with no VEP100 condition. In order to calculate the R^2 for hybrid models, we first calculate the total error sum of squares for the combined populations (concurrent and prospective) as the error sum of squares for the concurrent population plus the error sum of squares from the prospective population. At the same time, the corrected total sum of squares is calculated as the sum of squares adjusted for the mean of the overall population. Finally, the R^2 is defined as one minus the ratio of the error sum of squares to the corrected total sum of squares. This methodology has been previously used in the literature [6]. We obtain an R^2 for hybrid models of 0.2263 (model 6c), which is similar to the predictive power of the usual prospective model using demographic and health status information (model 2b) but in which efficiency incentives are higher for provision of pharmaceutical products for 87.73% of the population, and there are no incentives for risk selection for the provision of pharmaceutical products in those patients with VEP100 conditions who are thought to be at risk of suffering risk selection.

In a further attempt to check the validity of the hybrid risk adjustment model, we proceed to develop a sensitivity analysis by changing the criteria for the division of the population. Thus, models 7 to 9 are similar to models 4 to 6, but in which the prospective risk adjustment is assigned for patients suffering less than two VEP100 conditions (96.98%), and the concurrent risk adjustment for patients with at least two VEP100 conditions (3.02%). In this model, the

efficiency incentives remain for a higher proportion of the population, but the predictive power in the prospective model decreases to an R^2 of 0.2199 (model 8c) because we have included patients with high variation in drug expenditures within CRG categories in the sub-sample. Therefore, there still exist incentives for risk selection in this hybrid model for patients suffering one VEP100 condition. Differently, the predictive power of the concurrent model for those patients with more than one VEP100 conditions hugely increases (R^2 of 0.3185 in model 7c), and the R^2 of hybrid models remains in the same level (R^2 of 0.2395 in model 9c versus an R^2 of 0.2263 in model 6c). The interpretation of this result is that the free variation in drug expenditures is specially concentrated in patients suffering one VEP100 conditions because most of them still belong to relatively healthy CRG categories. It is important to note that our R^2 are probably higher than should be expected in other national samples in that all of the providers are from a narrow geographic area, and hence drug expenditure and practice style variations are reduced compared to other greater national samples.

Table 4 presents the predictive ratios for the different risk adjustment models and by different groups of population. In the validating sample, the proportion of population with and without VEP100 conditions slightly varies (12.39% have at least one VEP100 condition and 3.05% have more than one). Results support those from the R^2 presented. All models (prospective, concurrent, and hybrid) benefits from including a dummy variable with the presence of VEP100 conditions. Hybrid models improve the predictive ratio for patients in most of CRG categories, but especially when patients are ordered by deciles of drug expenditures or by presence of VEP100 conditions. Also, the importance of prevalence of clinical conditions is evidenced by the fact that for patients at some CRG categories, prospective models present a better predictive ratio (closer to 1) than concurrent models, which is explained by the timing of the diagnosis during the natural year.

5. Conclusions

Risk adjustment models do not solve completely the tradeoff between efficiency in the provision and risk selection because of the high variation in expenditures within groups. While prospective models promote efficiency, they also are unable to avoid the potential incentives for risk

selection, and concurrent models neither provide incentives for risk selection nor for efficiency. In this paper we follow a hybrid risk adjustment approach in the literature which proposes to divide population into two groups, maximizing incentives for efficiency for those patients not suffering a specific set of conditions, and eliminating incentives for risk selection for those suffering that set of specific health conditions. We utilize the VEP100 set of verifiable, expensive, predictive conditions used in the literature. We include the presence of those conditions as a risk adjuster in the prospective and concurrent models because they explain at some extent the high variation in drug expenditures within groups. Although it is not shown here or elsewhere that this is the optimal way of dividing population, in this paper we show how it improves efficiency incentives in the delivery of pharmaceutical benefits for the population in a county in Catalonia served by an integrated healthcare organization, and eliminates incentives for risk selection for those patients at risk of being deviated to other counties. Risk selection in this specific case is easily verifiable since all individuals are under universal coverage and any denial or transfer to another area would be noticed by the information system of the Catalan Health Service.

The hybrid model associates the concurrent part of the reimbursement formula to fixed amounts according to the verifiable presence of some expensive conditions, and compensates deviations in drug expenditures which are explained by morbidity given its high variation within groups. In such a situation there is a risk of up-coding, although this behavior could be addressed through targeted auditing. In this research we have taken the VEP conditions as given. However, we understand that there is a need to define specific VEP conditions for pharmaceutical expenditure since their impact in pharmaceutical expenditure might be different than that in total health expenditure. Future research is needed towards the application of hybrid risk adjustment models comparable to other studies in the literature and with respect to the search of the optimal set of specific conditions in specific environments that solves the tradeoff between efficiency and selection at a minimal cost. Pharmaceutical expenditure is only one part of total expenditures. Therefore, applications focusing on total expenditures for health benefits package is the next research approach that is needed.

Acknowledgements

This research was supported by an unrestricted educational grant awarded jointly to the Universities Carlos III de Madrid and Pompeu Fabra de Barcelona by The Merck Foundation, the philanthropic arm of Merck Co. Inc., White House Station, New Jersey, USA. The authors also thank support from the project 128/01/2004 funded by Catalan Agency for Health Technology Assessment (Agència d'Avaluació de Tecnologia i Recerca Mèdiques de Catalunya - AATRM). We thank Jordi Coderch and Jordi Calsina from *Serveis de Salut Integrats del Baix Empordà* for their support with the data and their comments; and Norbert Goldfield and Jon Eisenlander from *3M Health Information Systems* for their contribution to the morbidity measurement. We also thank Randy Ellis, Pedro Pita for their helpful comments. Remaining errors are the authors' responsibility.

References

1. Antioch, K.M., Ellis, R.P., Gillett, S., Borovnicar, D., Marshall, R.P.: Risk adjustment policy options for casemix funding: international lessons in financing reform. Eur. J. Health Econ. 8, 195-212 (2007).
2. Beebe, J.C.:An Outlier Pool for Medicare HMO Payments. Health Care Financing Review 14(1):59-63 (1992).
3. Behrend, C., Buchner, F., Happich, M., Holle, R., Reitmeir, P., Wasem, J.: Risk-adjusted capitation payments: how well do principal inpatient diagnosis-based models work in the German situation? Results from a large data set. Eur. J. Health Econ. 8, 31-39 (2007).
4. Berk, M.L., Monheit, A.C.: The Concentration of Health Care Expenditures, Revisited. Health Affairs 20(2):9-18 (2001).
5. Cutler, D.M., Landrum, M.N., Stewart, K.A.: Intensive medical care and cardiovascular disease disability reductions. NBER Working Paper 12184 (2006).
6. Dudley, R.A., Medlin C.A., Hammann, L.B., Cisternas, M.G., Brand, R., Rennie, D.J., Luft, H.: The Best of Both Worlds? The Potential of Hybrid Prospective/Concurrent Risk Adjustment. Medical Care 41(1):56–69 (2003).
7. Ellis, R.P., McGuire, T.G.: Insurance Principles and the Design of Prospective Payment Systems. Journal of Health Economics 7:215-237 (1988).
8. Ettner, S.L., Frank, R.G., McGuire, T.G., Hermann, R.C.: Risk adjustment alternatives in paying for behavioral health care under Medicaid. Health Services Research 36:793–811 (2001).
9. García-Goñi, M.: El Ajuste de Riesgos en los mercados sanitarios; Experiencias Europeas. In *Integración asistencial: fundamentos, experiencias y vías de avance*, edited by P. Ibern, pp. 187-208. Barcelona, Spain: Masson (2006).
10. García-Goñi, M., Ibern, P.: Predictability of drug expenditures: an application using morbidity data. Health Economics 17(1): 119-126 (2008).
11. García-Sempere, A., Peiró, S.: Gasto farmacéutico en atención primaria: variables asociadas y asignación de presupuestos de farmacia por zonas de salud. Gaceta Sanitaria 15:32-40 (2001).

12. Healey, A.T., Yule, B.F., Reid, J.P.: Variation in general practice prescribing costs and implications for budget setting. Health Economics 3(1):1-47 (1994).
13. Hughes, J.S., Averill, R.F., Eisenhandler, J., Goldfield, N.I., Muldoon, J., Neff, J.M., Gay, J.C.: Clinical Risk Groups (CRGs): a classification system for risk-adjusted capitation-based payment and health care management. Medical Care 42(1):81–90 (2004).
14. Keeler, E.B., Carter, T.: Insurance Aspects of DRG Outlier Payments. Journal of Health Economics 7:193-214 (1988).
15. Luft, H.S., Dudley, R.A.: Assessing Risk Adjustment Approaches under Non-Random Selection. Inquiry 41:203–217 (2004).
16. Morgan, S.G.: Prescription Drug Expenditures and Population Demographics. Health Services Research 41(2):411-428 (2006).
17. New York Times. A Cancer Drug's Big Price Rise Is Cause for Concern. March 12, 2006.
18. New York Times. Cancer drugs offer hope, but at a huge expense. July 12, 2005.
19. Newhouse, J.P.: Reimbursing Health Plans and Health Providers: Efficiency in Production versus Selection. Journal of Economic Literature 34:1236-1263 (1996).
20. Rice, N., Dixon, P., Lloyd, D.C., Roberts, D.: Derivation of a needs based capitation formula for allocating prescribing budgets to health authorities and primary care groups in England: regression analysis. British Medical Journal 320: 284-288 (2000).
21. Robinson, J.W.: Regression Tree Boosting to Adjust Health Care Cost Predictions for Diagnostic Mix. Health Services Research (OnlineEarly Articles) doi:10.1111/j.1475-6773.2007.00761.x (2007).
22. Rosen, A.B., Hamel, M.B., Weinstein, M.C., Cutler, D.M., Fendrick, A.M, Vijan. S.: Cost-effectiveness of full medicare coverage of angiotensing-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143(2) 89-99 (2005).
23. Thomas, J.W.: Should Episode-Based Economic Profiles Be Risk Adjusted to Account for Differences in Patients' Health Risks?. Health Services Research 41(2):581-598 (2006).
24. Van Barneveld, E.M., Lamers, L.M., Van Vliet, R.C.J.A., Van de Ven, W.P.M.M.: Risk Sharing as a Supplement to Imperfect Capitation in Health Insurance: a Tradeoff Between Selection and Efficiency. Journal of Health Economics 20:147-168 (2001).

25. Van Barneveld, E.M., Lamers, L.M., Van Vliet, R.C.J.A, Van de Ven, W.P.M.M.: Mandatory Pooling as a Supplement to Risk-Adjustment Capitation Payments in a Competitive Health Insurance Market. Social Science and Medicine 47:223-232 (1997).
26. Van de Ven, W.P.M.M., Ellis, R.P.: Risk adjustment in Competitive Health Plan Markets. In *Handbook of Health Economics*, edited by A.J. Culyer and J.P. Newhouse. Amsterdam, The Netherlands: Elsevier (2000).
27. Van de Ven, W.P.M.M., Van Vliet, R.C.J.A., Schut, E., Van Barneveld, E.M.: Access Coverage for High-Risks in a Competitive Individual Health Insurance Market: Via Premium Rate Restrictions or Risk-Adjustment Premium Subsidies?. Journal of Health Economics 19:311-339 (2000).
28. Winkelman, R., Mehmud, S.A.: A Comparative Analysis of Claims-Based Tools for Health Risk Assessment. Society of Actuaries sponsored Research Project [accessed on July 21, 2007]. Available at: http://www.soa.org/soaweb/files/pdf/risk-assessmentc.pdf (2007).
29. Wrobel, M.V., Doshi, J., Stuart, B.C., Briesacher, B.: Predictability of prescription drug expenditures for Medicare beneficiaries. Health Care Financing Review 25(2):37-46 (2003).
30. Zhao, Y., Ash, A.S., Ellis, R.P., Ayanian, J.Z., Pope, G.C., Bowen, B., Weyuker, L.: Predicting pharmacy costs and other medical costs using diagnoses and drug claims. Medical Care 43(1):34-43 (2005).
31. Zhao, Y., Ellis, R.P., Ash, A.S., Calabrese, D., Ayanian, J.Z., Slaughter, J.P., Weyuker, L., Bowen, B.: Measuring population health risks using inpatient diagnoses and outpatient pharmacy data. Health Services Research 36:180-93 (2001).
32. Zuvekas, S.H., Cohen, J.W.: Prescription Drugs And The Changing Concentration Of Health Care Expenditures. Health Affairs 26(1):249-257 (2007).

Table 1: Descriptive statistics of the sample. N=87436 and relative cost weights by the presence of Verifiable Expensive Predictive (VEP100) conditions.

Gender	**Number**	**Proportion**
Males	44181	50.53%
Females	43255	49.47%
	Average	Std. Deviation
Age	39.13	22.64

	2002			2003		
Average pharmacy cost	148.94			182.68		
Presence of VEP100 Conditions	**Mean Annual Cost**	**Mean Annual Relative Cost Weight**	**Sum patients**	**Mean Annual Cost**	**Mean Annual Relative Cost Weight**	**Sum patients**
Patients with no VEP100 conditions	92.73	0.62	77807 (88.98%)	106.83	0.58	76706 (87.72%)
Patients with at least one VEP100 condition	603.05	4.05	9629 (11.02%)	724.85	3.97	10730 (12.28%)
all patients	148.93	1.00	87436 (100%)	182.67	1.00	87436 (100%)

Table 2: Distribution of health conditions and presence of VEP100 in patients.

Health conditions by Clinical Risk Groups (highest level of aggregation)	Patients with no VEP100 in 2002		Patients with at least one VEP100 in 2002		Patients with no VEP100 in 2003		Patients with at least one VEP100 in 2003	
	N	% by CRG	N	% by CRG	N	% by CRG	N	% by CRG
Healthy	63177	96.69	2165	3.31	61485	96.13	2473	3.87
History Of Significant Acute Disease	5364	79.00	1426	21.00	5538	76.11	1738	23.89
Single Minor Chronic Disease	3384	87.87	467	12.13	3783	88.84	475	11.16
Minor Chronic Disease In Multiple Organ Systems	371	77.45	108	22.55	439	82.99	90	17.01
Single Dominant Or Moderate Chronic Disease	4555	58.45	3238	41.55	4522	55.93	3563	44.07
Significant Chronic Disease In Multiple Organ Systems	932	34.98	1732	65.02	918	33.10	1855	66.90
Dominant Chronic Disease In Three Or More Organ Systems	17	10.06	152	89.94	13	6.99	173	93.01
Dominant, Metastatic, And Complicated Malignancies	3	1.35	220	98.65	4	1.69	232	98.31
Catastrophic Conditions	4	3.20	121	96.80	4	2.96	131	97.04

Table 3: R-squared of the different risk adjustment models

Predictors	R-squared	Percentage of patients	Timing	N	Number of parameters
Model using only demographic information					
M1: Only demographic information	0.0905	100.00%	Prospective	87436	12
Prospective models including diagnostic and procedures information					
M2a: Only information on CRG conditions	0.2187	100.00%	Prospective	87436	82
M2b: Demographic and CRG conditions information	0.2458	100.00%	Prospective	87436	94
M2c: Demographic, CRG and existence of VEP100 information	0.2783	100.00%	Prospective	87436	194
Concurrent models including diagnostic and procedures information					
M3a: Only information on CRG conditions	0.2253	100.00%	Concurrent	87436	82
M3b: Demographic and CRG conditions information	0.2506	100.00%	Concurrent	87436	94
M3c: Demographic, CRG and existence of VEP100 information	0.2893	100.00%	Concurrent	87436	194
Dividing the sample between those with and without VEP100 in 2003					
M4a: Only information on CRG conditions	0.1480	12.27%	Concurrent	10730	82
M4b: Demographic and CRG conditions information	0.1616	12.27%	Concurrent	10730	94
M4c: Demographic, CRG and VEP information	0.2099	12.27%	Concurrent	10730	194
M5a: Only information on CRG conditions	0.1886	87.73%	Prospective	76706	82
M5b: Demographic and CRG conditions information	0.2535	87.73%	Prospective	76706	94
M5c: Demographic, CRG and VEP information	0.2769	87.73%	Prospective	76706	194
M6a: Hybrid Model (concurrent m4a for 12.27 and prospective m5a for 87.73%)	0.1579	87.73%+12.27%	Hybrid	87436	82
M6b: Hybrid Model (concurrent m4b for 12.27% and prospective m5b for 87.73%)	0.1841	87.73%+12.27%	Hybrid	87436	94
M6c: Hybrid Model (concurrent m4c for 12.27% and prospective m5c for 87.73%)	0.2263	87.73%+12.27%	Hybrid	87436	194
Dividing the sample between those with one or none VEP100 and those with at least two VEP100 in 2003					
M7a: Only information on CRG conditions	0.2084	3.02%	Concurrent	2640	82
M7b: Demographic and CRG conditions information	0.2193	3.02%	Concurrent	2640	94
M7c: Demographic, CRG and VEP information	0.3185	3.02%	Concurrent	2640	194
M8a: Only information on CRG conditions	0.1681	96.98%	Prospective	84796	82
M8b: Demographic and CRG conditions information	0.1982	96.98%	Prospective	84796	94
M8c: Demographic, CRG and VEP information	0.2199	96.98%	Prospective	84796	194
M9a: Hybrid Model (concurrent m7a for 3.02% and prospective m8a for 96.98%)	0.1761	96.98%+3.02%	Hybrid	87436	82
M9b: Hybrid Model (concurrent m7b for 3.02% and prospective m8b for 96.98%)	0.2023	96.98%+3.02%	Hybrid	87436	94
M9c: Hybrid Model (concurrent m7c for 3.02% and prospective m8c for 96.98%)	0.2395	96.98%+3.02%	Hybrid	87436	194

Table 4: Predictive Ratios for the different risk adjustment models

		Prospective models			Concurrent models		Hybrid models dividing patients with and without VEP100 in 2003		Hybrid models dividing patients with 0 or 1, and those with at least two VEP100 in 2003	
	N from validating subsample of 43416	M1: Only demographic information	M2b: Demographic and CRG conditions information	M2c: Demographic, CRG and VEP100 information	M3b: Demographic and CRG conditions information	M3c: Demographic, CRG and VEP100 information	M6b: Hybrid Model (concurrent m4b for 12.39% and prospective m5b for 87.61%)	M6d: Hybrid Model (concurrent m4c for 12.39% and prospective m5c for 87.61%)	M9b: Hybrid Model (concurrent m7b for 3.05% and prospective m8b for 96.95%)	M9d: Hybrid Model (concurrent m7c for 3.05% and prospective m8c for 96.95%)
Predictive Ratios by health conditions in 2003										
Healthy	32547	1.8516	0.9416	0.9423	1.2606	1.2242	1.0730	1.0516	0.9750	0.9740
History Of Significant Acute Disease	3338	0.8333	1.1218	1.1333	0.9850	0.9858	1.0301	1.0153	1.1353	1.1414
Single Minor Chronic Disease	1905	0.9179	0.9844	0.9828	0.9313	0.9153	1.0429	1.0198	1.0101	1.0135
Minor Chronic Disease In Multiple Organ Systems	232	0.8046	1.2132	1.2062	0.9295	1.0080	1.2065	1.2916	1.1707	1.1778
Single Dominant Or Moderate Chronic Disease	3870	0.6292	0.9970	0.9934	0.8519	0.8658	0.9616	0.9714	1.0009	1.0035
Significant Chronic Disease In Multiple Organ Systems	1275	0.4729	0.9783	0.9769	0.7837	0.8063	0.8907	0.8832	0.9399	0.9395
Dominant Chronic Disease In Three Or More Organ Systems	89	0.3155	0.9201	0.9677	0.6741	0.7186	0.7674	0.7815	0.8349	0.8645
Dominant, Metastatic, And Complicated Malignancies	101	0.3321	0.6679	0.6940	0.5728	0.5636	0.6099	0.5828	0.5703	0.5531
Catastrophic Conditions	59	0.0389	1.1060	0.9949	0.7480	0.7202	0.8082	0.7859	0.9617	0.9390
Predictive Ratios by deciles of drug expenditures in 2003										
decile 1 to 5	21782	98.3804	48.5114	47.1167	39.3490	37.7547	44.1155	42.9303	46.5413	45.7752
decile 6	4313	5.6628	5.5222	5.3143	5.8729	5.5279	5.0550	4.7754	5.3420	5.1908
decile 7	4348	3.2237	3.4102	3.2960	3.5795	3.3922	3.2857	3.1337	3.3608	3.2837
decile 8	4369	1.9669	2.1467	2.0881	2.2648	2.1726	2.1208	2.0403	2.1061	2.0471
decile 9	4333	1.0562	1.2088	1.1731	1.2506	1.2123	1.2379	1.1950	1.2195	1.1880
decile 10	4271	0.3301	0.4863	0.5086	0.4894	0.5175	0.5096	0.5291	0.4999	0.5213
Predictive Ratios by VEP100 procedures										
no VEP100 in 2003	38142	1.5202	1.2262	1.1770	1.1110	1.0197	1.0154	1.0130	1.1599	1.1266
at least one VEP100 in 2003	5274	0.4703	0.7406	0.7858	0.8440	0.9294	0.9563	0.9421	0.8093	0.8454
zero or one VEP100 in 2003	42118	1.1630	1.0703	1.0509	1.0328	0.9951	1.0259	1.0013	1.0050	1.0025
At least two VEP100 in 2003	1298	0.3777	0.6608	0.7237	0.7703	0.8972	0.8295	0.8865	0.9196	0.9333

FUNDACIÓN DE LAS CAJAS DE AHORROS

DOCUMENTOS DE TRABAJO

Últimos números publicados

159/2000 Participación privada en la construcción y explotación de carreteras de peaje
Ginés de Rus, Manuel Romero y Lourdes Trujillo

160/2000 Errores y posibles soluciones en la aplicación del *Value at Risk*
Mariano González Sánchez

161/2000 Tax neutrality on saving assets. The spahish case before and after the tax reform
Cristina Ruza y de Paz-Curbera

162/2000 Private rates of return to human capital in Spain: new evidence
F. Barceinas, J. Oliver-Alonso, J.L. Raymond y J.L. Roig-Sabaté

163/2000 El control interno del riesgo. Una propuesta de sistema de límites
riesgo neutral
Mariano González Sánchez

164/2001 La evolución de las políticas de gasto de las Administraciones Públicas en los años 90
Alfonso Utrilla de la Hoz y Carmen Pérez Esparrells

165/2001 Bank cost efficiency and output specification
Emili Tortosa-Ausina

166/2001 Recent trends in Spanish income distribution: A robust picture of falling income inequality
Josep Oliver-Alonso, Xavier Ramos y José Luis Raymond-Bara

167/2001 Efectos redistributivos y sobre el bienestar social del tratamiento de las cargas familiares en el nuevo IRPF
Nuria Badenes Plá, Julio López Laborda, Jorge Onrubia Fernández

168/2001 The Effects of Bank Debt on Financial Structure of Small and Medium Firms in some European Countries
Mónica Melle-Hernández

169/2001 La política de cohesión de la UE ampliada: la perspectiva de España
Ismael Sanz Labrador

170/2002 Riesgo de liquidez de Mercado
Mariano González Sánchez

171/2002 Los costes de administración para el afiliado en los sistemas de pensiones basados en cuentas de capitalización individual: medida y comparación internacional.
José Enrique Devesa Carpio, Rosa Rodríguez Barrera, Carlos Vidal Meliá

172/2002 La encuesta continua de presupuestos familiares (1985-1996): descripción, representatividad y propuestas de metodología para la explotación de la información de los ingresos y el gasto.
Llorenc Pou, Joaquín Alegre

173/2002 Modelos paramétricos y no paramétricos en problemas de concesión de tarjetas de credito.
Rosa Puertas, María Bonilla, Ignacio Olmeda

174/2002 Mercado único, comercio intra-industrial y costes de ajuste en las manufacturas españolas.
José Vicente Blanes Cristóbal

175/2003 La Administración tributaria en España. Un análisis de la gestión a través de los ingresos y de los gastos.
Juan de Dios Jiménez Aguilera, Pedro Enrique Barrilao González

176/2003 The Falling Share of Cash Payments in Spain.
Santiago Carbó Valverde, Rafael López del Paso, David B. Humphrey
Publicado en "Moneda y Crédito" nº 217, pags. 167-189.

177/2003 Effects of ATMs and Electronic Payments on Banking Costs: The Spanish Case.
Santiago Carbó Valverde, Rafael López del Paso, David B. Humphrey

178/2003 Factors explaining the interest margin in the banking sectors of the European Union.
Joaquín Maudos y Juan Fernández Guevara

179/2003 Los planes de stock options para directivos y consejeros y su valoración por el mercado de valores en España.
Mónica Melle Hernández

180/2003 Ownership and Performance in Europe and US Banking – A comparison of Commercial, Co-operative & Savings Banks.
Yener Altunbas, Santiago Carbó y Phil Molyneux

181/2003 The Euro effect on the integration of the European stock markets.
Mónica Melle Hernández

182/2004 In search of complementarity in the innovation strategy: international R&D and external knowledge acquisition.
Bruno Cassiman, Reinhilde Veugelers

183/2004 Fijación de precios en el sector público: una aplicación para el servicio municipal de suministro de agua.
Mª Ángeles García Valiñas

184/2004 Estimación de la economía sumergida es España: un modelo estructural de variables latentes.
Ángel Alañón Pardo, Miguel Gómez de Antonio

185/2004 Causas políticas y consecuencias sociales de la corrupción.
Joan Oriol Prats Cabrera

186/2004 Loan bankers' decisions and sensitivity to the audit report using the belief revision model.
Andrés Guiral Contreras and José A. Gonzalo Angulo

187/2004 El modelo de Black, Derman y Toy en la práctica. Aplicación al mercado español.
Marta Tolentino García-Abadillo y Antonio Díaz Pérez

188/2004 Does market competition make banks perform well?.
Mónica Melle

189/2004 Efficiency differences among banks: external, technical, internal, and managerial
Santiago Carbó Valverde, David B. Humphrey y Rafael López del Paso

190/2004 Una aproximación al análisis de los costes de la esquizofrenia en españa: los modelos jerárquicos bayesianos
F. J. Vázquez-Polo, M. A. Negrín, J. M. Cavasés, E. Sánchez y grupo RIRAG

191/2004 Environmental proactivity and business performance: an empirical analysis
Javier González-Benito y Óscar González-Benito

192/2004 Economic risk to beneficiaries in notional defined contribution accounts (NDCs)
Carlos Vidal-Meliá, Inmaculada Domínguez-Fabian y José Enrique Devesa-Carpio

193/2004 Sources of efficiency gains in port reform: non parametric malmquist decomposition tfp index for Mexico
Antonio Estache, Beatriz Tovar de la Fé y Lourdes Trujillo

194/2004 Persistencia de resultados en los fondos de inversión españoles
Alfredo Ciriaco Fernández y Rafael Santamaría Aquilué

195/2005 El modelo de revisión de creencias como aproximación psicológica a la formación del juicio del auditor sobre la gestión continuada
Andrés Guiral Contreras y Francisco Esteso Sánchez

196/2005 La nueva financiación sanitaria en España: descentralización y prospectiva
David Cantarero Prieto

197/2005 A cointegration analysis of the Long-Run supply response of Spanish agriculture to the common agricultural policy
José A. Mendez, Ricardo Mora y Carlos San Juan

198/2005 ¿Refleja la estructura temporal de los tipos de interés del mercado español preferencia por la liquidez?
Magdalena Massot Perelló y Juan M. Nave

199/2005 Análisis de impacto de los Fondos Estructurales Europeos recibidos por una economía regional: Un enfoque a través de Matrices de Contabilidad Social
M. Carmen Lima y M. Alejandro Cardenete

200/2005 Does the development of non-cash payments affect monetary policy transmission?
Santiago Carbó Valverde y Rafael López del Paso

201/2005 Firm and time varying technical and allocative efficiency: an application for port cargo handling firms
Ana Rodríguez-Álvarez, Beatriz Tovar de la Fe y Lourdes Trujillo

202/2005 Contractual complexity in strategic alliances
Jeffrey J. Reuer y Africa Ariño

203/2005 Factores determinantes de la evolución del empleo en las empresas adquiridas por opa
Nuria Alcalde Fradejas y Inés Pérez-Soba Aguilar

204/2005 Nonlinear Forecasting in Economics: a comparison between Comprehension Approach versus Learning Approach. An Application to Spanish Time Series
Elena Olmedo, Juan M. Valderas, Ricardo Gimeno and Lorenzo Escot

205/2005 Precio de la tierra con presión urbana: un modelo para España
Esther Decimavilla, Carlos San Juan y Stefan Sperlich

206/2005 Interregional migration in Spain: a semiparametric analysis
Adolfo Maza y José Villaverde

207/2005 Productivity growth in European banking
Carmen Murillo-Melchor, José Manuel Pastor y Emili Tortosa-Ausina

208/2005 Explaining Bank Cost Efficiency in Europe: Environmental and Productivity Influences.
Santiago Carbó Valverde, David B. Humphrey y Rafael López del Paso

209/2005 La elasticidad de sustitución intertemporal con preferencias no separables intratemporalmente: los casos de Alemania, España y Francia.
Elena Márquez de la Cruz, Ana R. Martínez Cañete y Inés Pérez-Soba Aguilar

210/2005 Contribución de los efectos tamaño, book-to-market y momentum a la valoración de activos: el caso español.
Begoña Font-Belaire y Alfredo Juan Grau-Grau

211/2005 Permanent income, convergence and inequality among countries
José M. Pastor and Lorenzo Serrano

212/2005 The Latin Model of Welfare: Do 'Insertion Contracts' Reduce Long-Term Dependence?
Luis Ayala and Magdalena Rodríguez

213/2005 The effect of geographic expansion on the productivity of Spanish savings banks
Manuel Illueca, José M. Pastor and Emili Tortosa-Ausina

214/2005 Dynamic network interconnection under consumer switching costs
Ángel Luis López Rodríguez

215/2005 La influencia del entorno socioeconómico en la realización de estudios universitarios: una aproximación al caso español en la década de los noventa
Marta Rahona López

216/2005 The valuation of spanish ipos: efficiency analysis
Susana Álvarez Otero

217/2005 On the generation of a regular multi-input multi-output technology using parametric output distance functions
Sergio Perelman and Daniel Santin

218/2005 La gobernanza de los procesos parlamentarios: la organización industrial del congreso de los diputados en España
Gonzalo Caballero Miguez

219/2005 Determinants of bank market structure: Efficiency and political economy variables
Francisco González

220/2005 Agresividad de las órdenes introducidas en el mercado español: estrategias, determinantes y medidas de performance
David Abad Díaz

221/2005 Tendencia post-anuncio de resultados contables: evidencia para el mercado español
Carlos Forner Rodríguez, Joaquín Marhuenda Fructuoso y Sonia Sanabria García

222/2005 Human capital accumulation and geography: empirical evidence in the European Union
Jesús López-Rodríguez, J. Andrés Faíña y Jose Lopez Rodríguez

223/2005 Auditors' Forecasting in Going Concern Decisions: Framing, Confidence and Information Processing
Waymond Rodgers and Andrés Guiral

224/2005 The effect of Structural Fund spending on the Galician region: an assessment of the 1994-1999 and 2000-2006 Galician CSFs
José Ramón Cancelo de la Torre, J. Andrés Faíña and Jesús López-Rodríguez

225/2005 The effects of ownership structure and board composition on the audit committee activity: Spanish evidence
Carlos Fernández Méndez and Rubén Arrondo García

226/2005 Cross-country determinants of bank income smoothing by managing loan loss provisions
Ana Rosa Fonseca and Francisco González

227/2005 Incumplimiento fiscal en el irpf (1993-2000): un análisis de sus factores determinantes
Alejandro Estellér Moré

228/2005 Region versus Industry effects: volatility transmission
Pilar Soriano Felipe and Francisco J. Climent Diranzo

229/2005 Concurrent Engineering: The Moderating Effect Of Uncertainty On New Product Development Success
Daniel Vázquez-Bustelo and Sandra Valle

230/2005 On zero lower bound traps: a framework for the analysis of monetary policy in the 'age' of central banks
Alfonso Palacio-Vera

231/2005 Reconciling Sustainability and Discounting in Cost Benefit Analysis: a methodological proposal
M. Carmen Almansa Sáez and Javier Calatrava Requena

232/2005 Can The Excess Of Liquidity Affect The Effectiveness Of The European Monetary Policy?
Santiago Carbó Valverde and Rafael López del Paso

233/2005 Inheritance Taxes In The Eu Fiscal Systems: The Present Situation And Future Perspectives.
Miguel Angel Barberán Lahuerta

234/2006 Bank Ownership And Informativeness Of Earnings.
Víctor M. González

235/2006 Developing A Predictive Method: A Comparative Study Of The Partial Least Squares Vs Maximum Likelihood Techniques.
Waymond Rodgers, Paul Pavlou and Andres Guiral.

236/2006 Using Compromise Programming for Macroeconomic Policy Making in a General Equilibrium Framework: Theory and Application to the Spanish Economy.
Francisco J. André, M. Alejandro Cardenete y Carlos Romero.

237/2006 Bank Market Power And Sme Financing Constraints.
Santiago Carbó-Valverde, Francisco Rodríguez-Fernández y Gregory F. Udell.

238/2006 Trade Effects Of Monetary Agreements: Evidence For Oecd Countries.
Salvador Gil-Pareja, Rafael Llorca-Vivero y José Antonio Martínez-Serrano.

239/2006 The Quality Of Institutions: A Genetic Programming Approach.
Marcos Álvarez-Díaz y Gonzalo Caballero Miguez.

240/2006 La interacción entre el éxito competitivo y las condiciones del mercado doméstico como determinantes de la decisión de exportación en las Pymes.
Francisco García Pérez.

241/2006 Una estimación de la depreciación del capital humano por sectores, por ocupación y en el tiempo.
Inés P. Murillo.

242/2006 Consumption And Leisure Externalities, Economic Growth And Equilibrium Efficiency.
Manuel A. Gómez.

243/2006 Measuring efficiency in education: an analysis of different approaches for incorporating non-discretionary inputs.
Jose Manuel Cordero-Ferrera, Francisco Pedraja-Chaparro y Javier Salinas-Jiménez

244/2006 Did The European Exchange-Rate Mechanism Contribute To The Integration Of Peripheral Countries?.
Salvador Gil-Pareja, Rafael Llorca-Vivero y José Antonio Martínez-Serrano

245/2006 Intergenerational Health Mobility: An Empirical Approach Based On The Echp.
Marta Pascual and David Cantarero

246/2006 Measurement and analysis of the Spanish Stock Exchange using the Lyapunov exponent with digital technology.
Salvador Rojí Ferrari and Ana Gonzalez Marcos

247/2006 Testing For Structural Breaks In Variance Withadditive Outliers And Measurement Errors.
Paulo M.M. Rodrigues and Antonio Rubia

248/2006 The Cost Of Market Power In Banking: Social Welfare Loss Vs. Cost Inefficiency.
Joaquín Maudos and Juan Fernández de Guevara

249/2006 Elasticidades de largo plazo de la demanda de vivienda: evidencia para España (1885-2000).
Desiderio Romero Jordán, José Félix Sanz Sanz y César Pérez López

250/2006 Regional Income Disparities in Europe: What role for location?.
Jesús López-Rodríguez and J. Andrés Faíña

251/2006 Funciones abreviadas de bienestar social: Una forma sencilla de simultanear la medición de la eficiencia y la equidad de las políticas de gasto público.
Nuria Badenes Plá y Daniel Santín González

252/2006 “The momentum effect in the Spanish stock market: Omitted risk factors or investor behaviour?”.
Luis Muga and Rafael Santamaría

253/2006 Dinámica de precios en el mercado español de gasolina: un equilibrio de colusión tácita.
Jordi Perdiguero García

254/2006 Desigualdad regional en España: renta permanente versus renta corriente.
José M.Pastor, Empar Pons y Lorenzo Serrano

255/2006 Environmental implications of organic food preferences: an application of the impure public goods model.
Ana Maria Aldanondo-Ochoa y Carmen Almansa-Sáez

256/2006 Family tax credits versus family allowances when labour supply matters: Evidence for Spain.
José Felix Sanz-Sanz, Desiderio Romero-Jordán y Santiago Álvarez-García

257/2006 La internacionalización de la empresa manufacturera española: efectos del capital humano genérico y específico.
José López Rodríguez

258/2006 Evaluación de las migraciones interregionales en España, 1996-2004.
María Martínez Torres

259/2006 Efficiency and market power in Spanish banking.
Rolf Färe, Shawna Grosskopf y Emili Tortosa-Ausina.

260/2006 Asimetrías en volatilidad, beta y contagios entre las empresas grandes y pequeñas cotizadas en la bolsa española.
Helena Chuliá y Hipòlit Torró.

261/2006 Birth Replacement Ratios: New Measures of Period Population Replacement.
José Antonio Ortega.

262/2006 Accidentes de tráfico, víctimas mortales y consumo de alcohol.
José Mª Arranz y Ana I. Gil.

263/2006 Análisis de la Presencia de la Mujer en los Consejos de Administración de las Mil Mayores Empresas Españolas.
Ruth Mateos de Cabo, Lorenzo Escot Mangas y Ricardo Gimeno Nogués.

264/2006 Crisis y Reforma del Pacto de Estabilidad y Crecimiento. Las Limitaciones de la Política Económica en Europa.
Ignacio Álvarez Peralta.

265/2006 Have Child Tax Allowances Affected Family Size? A Microdata Study For Spain (1996-2000).
Jaime Vallés-Giménez y Anabel Zárate-Marco.

266/2006 Health Human Capital And The Shift From Foraging To Farming.
Paolo Rungo.

267/2006 Financiación Autonómica y Política de la Competencia: El Mercado de Gasolina en Canarias.
Juan Luis Jiménez y Jordi Perdiguero.

268/2006 El cumplimiento del Protocolo de Kyoto para los hogares españoles: el papel de la imposición sobre la energía.
Desiderio Romero-Jordán y José Félix Sanz-Sanz.

269/2006 Banking competition, financial dependence and economic growth
Joaquín Maudos y Juan Fernández de Guevara

270/2006 Efficiency, subsidies and environmental adaptation of animal farming under CAP
Werner Kleinhanß, Carmen Murillo, Carlos San Juan y Stefan Sperlich

271/2006 Interest Groups, Incentives to Cooperation and Decision-Making Process in the European Union
A. Garcia-Lorenzo y Jesús López-Rodríguez

272/2006 Riesgo asimétrico y estrategias de momentum en el mercado de valores español
Luis Muga y Rafael Santamaría

273/2006 Valoración de capital-riesgo en proyectos de base tecnológica e innovadora a través de la teoría de opciones reales
Gracia Rubio Martín

274/2006 Capital stock and unemployment: searching for the missing link
Ana Rosa Martínez-Cañete, Elena Márquez de la Cruz, Alfonso Palacio-Vera and Inés Pérez-Soba Aguilar

275/2006 Study of the influence of the voters' political culture on vote decision through the simulation of a political competition problem in Spain
Sagrario Lantarón, Isabel Lillo, Mª Dolores López and Javier Rodrigo

276/2006 Investment and growth in Europe during the Golden Age
Antonio Cubel and Mª Teresa Sanchis

277/2006 Efectos de vincular la pensión pública a la inversión en cantidad y calidad de hijos en un modelo de equilibrio general
Robert Meneu Gaya

278/2006 El consumo y la valoración de activos
Elena Márquez y Belén Nieto

279/2006 Economic growth and currency crisis: A real exchange rate entropic approach
David Matesanz Gómez y Guillermo J. Ortega

280/2006 Three measures of returns to education: An illustration for the case of Spain
María Arrazola y José de Hevia

281/2006 Composition of Firms versus Composition of Jobs
Antoni Cunyat

282/2006 La vocación internacional de un holding tranviario belga: la Compagnie Mutuelle de Tram-ways, 1895-1918
Alberte Martínez López

283/2006 Una visión panorámica de las entidades de crédito en España en la última década.
Constantino García Ramos

284/2006 Foreign Capital and Business Strategies: a comparative analysis of urban transport in Madrid and Barcelona, 1871-1925
Alberte Martínez López

285/2006 Los intereses belgas en la red ferroviaria catalana, 1890-1936
Alberte Martínez López

286/2006 The Governance of Quality: The Case of the Agrifood Brand Names
Marta Fernández Barcala, Manuel González-Díaz y Emmanuel Raynaud

287/2006 Modelling the role of health status in the transition out of malthusian equilibrium
Paolo Rungo, Luis Currais and Berta Rivera

288/2006 Industrial Effects of Climate Change Policies through the EU Emissions Trading Scheme
Xavier Labandeira and Miguel Rodríguez

289/2006 Globalisation and the Composition of Government Spending: An analysis for OECD countries
Norman Gemmell, Richard Kneller and Ismael Sanz

290/2006 La producción de energía eléctrica en España: Análisis económico de la actividad tras la liberalización del Sector Eléctrico
Fernando Hernández Martínez

291/2006 Further considerations on the link between adjustment costs and the productivity of R&D investment: evidence for Spain
Desiderio Romero-Jordán, José Félix Sanz-Sanz and Inmaculada Álvarez-Ayuso

292/2006 Una teoría sobre la contribución de la función de compras al rendimiento empresarial
Javier González Benito

293/2006 Agility drivers, enablers and outcomes: empirical test of an integrated agile manufacturing model
Daniel Vázquez-Bustelo, Lucía Avella and Esteban Fernández

294/2006 Testing the parametric vs the semiparametric generalized mixed effects models
María José Lombardía and Stefan Sperlich

295/2006 Nonlinear dynamics in energy futures
Mariano Matilla-García

296/2006 Estimating Spatial Models By Generalized Maximum Entropy Or How To Get Rid Of W
Esteban Fernández Vázquez, Matías Mayor Fernández and Jorge Rodriguez-Valez

297/2006 Optimización fiscal en las transmisiones lucrativas: análisis metodológico
Félix Domínguez Barrero

298/2006 La situación actual de la banca online en España
Francisco José Climent Diranzo y Alexandre Momparler Pechuán

299/2006 Estrategia competitiva y rendimiento del negocio: el papel mediador de la estrategia y las capacidades productivas
Javier González Benito y Isabel Suárez González

300/2006 A Parametric Model to Estimate Risk in a Fixed Income Portfolio
Pilar Abad and Sonia Benito

301/2007 Análisis Empírico de las Preferencias Sociales Respecto del Gasto en Obra Social de las Cajas de Ahorros
Alejandro Esteller-Moré, Jonathan Jorba Jiménez y Albert Solé-Ollé

302/2007 Assessing the enlargement and deepening of regional trading blocs: The European Union case
Salvador Gil-Pareja, Rafael Llorca-Vivero y José Antonio Martínez-Serrano

303/2007 ¿Es la Franquicia un Medio de Financiación?: Evidencia para el Caso Español
Vanesa Solís Rodríguez y Manuel González Díaz

304/2007 On the Finite-Sample Biases in Nonparametric Testing for Variance Constancy
Paulo M.M. Rodrigues and Antonio Rubia

305/2007 Spain is Different: Relative Wages 1989-98
José Antonio Carrasco Gallego

306/2007 Poverty reduction and SAM multipliers: An evaluation of public policies in a regional framework
Francisco Javier De Miguel-Vélez y Jesús Pérez-Mayo

307/2007 La Eficiencia en la Gestión del Riesgo de Crédito en las Cajas de Ahorro
Marcelino Martínez Cabrera

308/2007 Optimal environmental policy in transport: unintended effects on consumers' generalized price
M. Pilar Socorro and Ofelia Betancor

309/2007 Agricultural Productivity in the European Regions: Trends and Explanatory Factors
Roberto Ezcurra, Belen Iráizoz, Pedro Pascual and Manuel Rapún

310/2007 Long-run Regional Population Divergence and Modern Economic Growth in Europe: a Case Study of Spain
María Isabel Ayuda, Fernando Collantes and Vicente Pinilla

311/2007 Financial Information effects on the measurement of Commercial Banks' Efficiency
Borja Amor, María T. Tascón and José L. Fanjul

312/2007 Neutralidad e incentivos de las inversiones financieras en el nuevo IRPF
Félix Domínguez Barrero

313/2007 The Effects of Corporate Social Responsibility Perceptions on The Valuation of Common Stock
Waymond Rodgers , Helen Choy and Andres Guiral-Contreras

314/2007 Country Creditor Rights, Information Sharing and Commercial Banks' Profitability Persistence across the world
Borja Amor, María T. Tascón and José L. Fanjul

315/2007 ¿Es Relevante el Déficit Corriente en una Unión Monetaria? El Caso Español
Javier Blanco González y Ignacio del Rosal Fernández

316/2007 The Impact of Credit Rating Announcements on Spanish Corporate Fixed Income Performance: Returns, Yields and Liquidity
Pilar Abad, Antonio Díaz and M. Dolores Robles

317/2007 Indicadores de Lealtad al Establecimiento y Formato Comercial Basados en la Distribución del Presupuesto
Cesar Augusto Bustos Reyes y Óscar González Benito

318/2007 Migrants and Market Potential in Spain over The XXth Century: A Test Of The New Economic Geography
Daniel A. Tirado, Jordi Pons, Elisenda Paluzie and Javier Silvestre

319/2007 El Impacto del Coste de Oportunidad de la Actividad Emprendedora en la Intención de los Ciudadanos Europeos de Crear Empresas
Luis Miguel Zapico Aldeano

320/2007 Los belgas y los ferrocarriles de vía estrecha en España, 1887-1936
Alberte Martínez López

321/2007 Competición política bipartidista. Estudio geométrico del equilibrio en un caso ponderado
Isabel Lillo, Mª Dolores López y Javier Rodrigo

322/2007 Human resource management and environment management systems: an empirical study
Mª Concepción López Fernández, Ana Mª Serrano Bedia and Gema García Piqueres

323/2007 Wood and industrialization. evidence and hypotheses from the case of Spain, 1860-1935.
Iñaki Iriarte-Goñi and María Isabel Ayuda Bosque

324/2007 New evidence on long-run monetary neutrality.
J. Cunado, L.A. Gil-Alana and F. Perez de Gracia

325/2007 Monetary policy and structural changes in the volatility of us interest rates.
Juncal Cuñado, Javier Gomez Biscarri and Fernando Perez de Gracia

326/2007 The productivity effects of intrafirm diffusion.
Lucio Fuentelsaz, Jaime Gómez and Sergio Palomas

327/2007 Unemployment duration, layoffs and competing risks.
J.M. Arranz, C. García-Serrano and L. Toharia

328/2007 El grado de cobertura del gasto público en España respecto a la UE-15
Nuria Rueda, Begoña Barruso, Carmen Calderón y Mª del Mar Herrador

329/2007 The Impact of Direct Subsidies in Spain before and after the CAP'92 Reform
Carmen Murillo, Carlos San Juan and Stefan Sperlich

330/2007 Determinants of post-privatisation performance of Spanish divested firms
Laura Cabeza García and Silvia Gómez Ansón

331/2007 ¿Por qué deciden diversificar las empresas españolas? Razones oportunistas versus razones económicas
Almudena Martínez Campillo

332/2007 Dynamical Hierarchical Tree in Currency Markets
Juan Gabriel Brida, David Matesanz Gómez and Wiston Adrián Risso

333/2007 Los determinantes sociodemográficos del gasto sanitario. Análisis con microdatos individuales
Ana María Angulo, Ramón Barberán, Pilar Egea y Jesús Mur

334/2007 Why do companies go private? The Spanish case
Inés Pérez-Soba Aguilar

335/2007 The use of gis to study transport for disabled people
Verónica Cañal Fernández

336/2007 The long run consequences of M&A: An empirical application
Cristina Bernad, Lucio Fuentelsaz and Jaime Gómez

337/2007 Las clasificaciones de materias en economía: principios para el desarrollo de una nueva clasificación
Valentín Edo Hernández

338/2007 Reforming Taxes and Improving Health: A Revenue-Neutral Tax Reform to Eliminate Medical and Pharmaceutical VAT
Santiago Álvarez-García, Carlos Pestana Barros y Juan Prieto-Rodriguez

339/2007 Impacts of an iron and steel plant on residential property values
Celia Bilbao-Terol

340/2007 Firm size and capital structure: Evidence using dynamic panel data
Víctor M. González and Francisco González

341/2007 ¿Cómo organizar una cadena hotelera? La elección de la forma de gobierno
Marta Fernández Barcala y Manuel González Díaz

342/2007 Análisis de los efectos de la decisión de diversificar: un contraste del marco teórico "Agencia-Stewardship"
Almudena Martínez Campillo y Roberto Fernández Gago

343/2007 Selecting portfolios given multiple eurostoxx-based uncertainty scenarios: a stochastic goal programming approach from fuzzy betas
Enrique Ballestero, Blanca Pérez-Gladish, Mar Arenas-Parra and Amelia Bilbao-Terol

344/2007 "El bienestar de los inmigrantes y los factores implicados en la decisión de emigrar"
Anastasia Hernández Alemán y Carmelo J. León

345/2007 Governance Decisions in the R&D Process: An Integrative Framework Based on TCT and Knowledge View of The Firm.
Andrea Martínez-Noya and Esteban García-Canal

346/2007 Diferencias salariales entre empresas públicas y privadas. El caso español
Begoña Cueto y Nuria Sánchez- Sánchez

347/2007 Effects of Fiscal Treatments of Second Home Ownership on Renting Supply
Celia Bilbao Terol and Juan Prieto Rodríguez

348/2007 Auditors' ethical dilemmas in the going concern evaluation
Andres Guiral, Waymond Rodgers, Emiliano Ruiz and Jose A. Gonzalo

349/2007 Convergencia en capital humano en España. Un análisis regional para el periodo 1970-2004
Susana Morales Sequera y Carmen Pérez Esparrells

350/2007 Socially responsible investment: mutual funds portfolio selection using fuzzy multiobjective programming
Blanca Mª Pérez-Gladish, Mar Arenas-Parra , Amelia Bilbao-Terol and Mª Victoria Rodríguez-Uría

351/2007 Persistencia del resultado contable y sus componentes: implicaciones de la medida de ajustes por devengo
Raúl Iñiguez Sánchez y Francisco Poveda Fuentes

352/2007 Wage Inequality and Globalisation: What can we Learn from the Past? A General Equilibrium Approach
Concha Betrán, Javier Ferri and Maria A. Pons

353/2007 Eficacia de los incentivos fiscales a la inversión en I+D en España en los años noventa
Desiderio Romero Jordán y José Félix Sanz Sanz

354/2007 Convergencia regional en renta y bienestar en España
Robert Meneu Gaya

355/2007 Tributación ambiental: Estado de la Cuestión y Experiencia en España
Ana Carrera Poncela

356/2007 Salient features of dependence in daily us stock market indices
Luis A. Gil-Alana, Juncal Cuñado and Fernando Pérez de Gracia

357/2007 La educación superior: ¿un gasto o una inversión rentable para el sector público?
Inés P. Murillo y Francisco Pedraja

358/2007 Effects of a reduction of working hours on a model with job creation and job destruction
Emilio Domínguez, Miren Ullibarri y Idoya Zabaleta

359/2007 Stock split size, signaling and earnings management: Evidence from the Spanish market
José Yagüe, J. Carlos Gómez-Sala and Francisco Poveda-Fuentes

360/2007 Modelización de las expectativas y estrategias de inversión en mercados de derivados
Begoña Font-Belaire

361/2008 Trade in capital goods during the golden age, 1953-1973
Mª Teresa Sanchis and Antonio Cubel

362/2008 El capital económico por riesgo operacional: una aplicación del modelo de distribución de pérdidas
Enrique José Jiménez Rodríguez y José Manuel Feria Domínguez

363/2008 The drivers of effectiveness in competition policy
Joan-Ramon Borrell and Juan-Luis Jiménez

364/2008 Corporate governance structure and board of directors remuneration policies: evidence from Spain
Carlos Fernández Méndez, Rubén Arrondo García and Enrique Fernández Rodríguez

365/2008 Beyond the disciplinary role of governance: how boards and donors add value to Spanish foundations
Pablo De Andrés Alonso, Valentín Azofra Palenzuela y M. Elena Romero Merino

366/2008 Complejidad y perfeccionamiento contractual para la contención del oportunismo en los acuerdos de franquicia
Vanesa Solís Rodríguez y Manuel González Díaz

367/2008 Inestabilidad y convergencia entre las regiones europeas
Jesús Mur, Fernando López y Ana Angulo

368/2008 Análisis espacial del cierre de explotaciones agrarias
Ana Aldanondo Ochoa, Carmen Almansa Sáez y Valero Casanovas Oliva

369/2008 Cross-Country Efficiency Comparison between Italian and Spanish Public Universities in the period 2000-2005
Tommaso Agasisti and Carmen Pérez Esparrells

370/2008 El desarrollo de la sociedad de la información en España: un análisis por comunidades autónomas
María Concepción García Jiménez y José Luis Gómez Barroso

371/2008 El medioambiente y los objetivos de fabricación: un análisis de los modelos estratégicos para su consecución
Lucía Avella Camarero, Esteban Fernández Sánchez y Daniel Vázquez-Bustelo

372/2008 Influence of bank concentration and institutions on capital structure: New international evidence
Víctor M. González and Francisco González

373/2008 Generalización del concepto de equilibrio en juegos de competición política
Mª Dolores López González y Javier Rodrigo Hitos

374/2008 Smooth Transition from Fixed Effects to Mixed Effects Models in Multi-level regression Models
María José Lombardía and Stefan Sperlich

375/2008 A Revenue-Neutral Tax Reform to Increase Demand for Public Transport Services
Carlos Pestana Barros and Juan Prieto-Rodriguez

376/2008 Measurement of intra-distribution dynamics: An application of different approaches to the European regions
Adolfo Maza, María Hierro and José Villaverde

377/2008 Migración interna de extranjeros y ¿nueva fase en la convergencia?
María Hierro y Adolfo Maza

378/2008 Efectos de la Reforma del Sector Eléctrico: Modelización Teórica y Experiencia Internacional
Ciro Eduardo Bazán Navarro

379/2008 A Non-Parametric Independence Test Using Permutation Entropy
Mariano Matilla-García and Manuel Ruiz Marín

380/2008 Testing for the General Fractional Unit Root Hypothesis in the Time Domain
Uwe Hassler, Paulo M.M. Rodrigues and Antonio Rubia

381/2008 Multivariate gram-charlier densities
Esther B. Del Brio, Trino-Manuel Ñíguez and Javier Perote

382/2008 Analyzing Semiparametrically the Trends in the Gender Pay Gap - The Example of Spain
Ignacio Moral-Arce, Stefan Sperlich, Ana I. Fernández-Saínz and Maria J. Roca

383/2008 A Cost-Benefit Analysis of a Two-Sided Card Market
Santiago Carbó Valverde, David B. Humphrey, José Manuel Liñares Zegarra and Francisco Rodriguez Fernandez

384/2008 A Fuzzy Bicriteria Approach for Journal Deselection in a Hospital Library
M. L. López-Avello, M. V. Rodríguez-Uría, B. Pérez-Gladish, A. Bilbao-Terol, M. Arenas-Parra

385/2008 Valoración de las grandes corporaciones farmaceúticas, a través del análisis de sus principales intangibles, con el método de opciones reales
Gracia Rubio Martín y Prosper Lamothe Fernández

386/2008 El marketing interno como impulsor de las habilidades comerciales de las pyme españolas: efectos en los resultados empresariales
Mª Leticia Santos Vijande, Mª José Sanzo Pérez, Nuria García Rodríguez y Juan A. Trespalacios Gutiérrez

387/2008 Understanding Warrants Pricing: A case study of the financial market in Spain
David Abad y Belén Nieto

388/2008 Aglomeración espacial, Potencial de Mercado y Geografía Económica: Una revisión de la literatura
Jesús López-Rodríguez y J. Andrés Faíña

389/2008 An empirical assessment of the impact of switching costs and first mover advantages on firm performance
Jaime Gómez, Juan Pablo Maícas

390/2008 Tender offers in Spain: testing the wave
Ana R. Martínez-Cañete y Inés Pérez-Soba Aguilar

391/2008 La integración del mercado español a finales del siglo XIX: los precios del trigo entre 1891 y 1905
Mariano Matilla García, Pedro Pérez Pascual y Basilio Sanz Carnero

392/2008 Cuando el tamaño importa: estudio sobre la influencia de los sujetos políticos en la balanza de bienes y servicios
Alfonso Echazarra de Gregorio

393/2008 Una visión cooperativa de las medidas ante el posible daño ambiental de la desalación
Borja Montaño Sanz

394/2008 Efectos externos del endeudamiento sobre la calificación crediticia de las Comunidades Autónomas
Andrés Leal Marcos y Julio López Laborda

395/2008 Technical efficiency and productivity changes in Spanish airports: A parametric distance functions approach
Beatriz Tovar & Roberto Rendeiro Martín-Cejas

396/2008 Network analysis of exchange data: Interdependence drives crisis contagion
David Matesanz Gómez & Guillermo J. Ortega

397/2008 Explaining the performance of Spanish privatised firms: a panel data approach
Laura Cabeza Garcia and Silvia Gomez Anson

398/2008 Technological capabilities and the decision to outsource R&D services
Andrea Martínez-Noya and Esteban García-Canal

399/2008 Hybrid Risk Adjustment for Pharmaceutical Benefits
Manuel García-Goñi, Pere Ibern & José María Inoriza